IRIS
MONNO, Laura
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.366
AS - Asia 5.056
EU - Europa 3.486
SA - Sud America 1.476
AF - Africa 311
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 3
AN - Antartide 1
Totale 23.707
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.214
SG - Singapore 1.981
BR - Brasile 1.183
CN - Cina 1.047
HK - Hong Kong 877
DE - Germania 630
IT - Italia 520
SE - Svezia 499
RU - Federazione Russa 400
UA - Ucraina 346
VN - Vietnam 337
FI - Finlandia 322
FR - Francia 257
GB - Regno Unito 237
IN - India 178
CI - Costa d'Avorio 134
BD - Bangladesh 113
AR - Argentina 99
ID - Indonesia 88
IQ - Iraq 68
CA - Canada 61
ZA - Sudafrica 57
BE - Belgio 56
MX - Messico 51
EC - Ecuador 47
IE - Irlanda 46
TR - Turchia 45
CO - Colombia 42
PK - Pakistan 42
SA - Arabia Saudita 41
VE - Venezuela 39
JP - Giappone 29
NL - Olanda 27
PL - Polonia 27
UZ - Uzbekistan 27
AT - Austria 25
KE - Kenya 23
PH - Filippine 22
MA - Marocco 21
MY - Malesia 19
TN - Tunisia 18
CL - Cile 17
PY - Paraguay 17
ES - Italia 16
JO - Giordania 16
DZ - Algeria 13
EG - Egitto 13
IL - Israele 13
AE - Emirati Arabi Uniti 12
GR - Grecia 12
IR - Iran 12
AZ - Azerbaigian 11
HR - Croazia 11
PE - Perù 11
LT - Lituania 9
NP - Nepal 9
RS - Serbia 9
KZ - Kazakistan 8
UY - Uruguay 8
BO - Bolivia 7
CR - Costa Rica 7
CZ - Repubblica Ceca 7
DO - Repubblica Dominicana 7
LB - Libano 7
OM - Oman 7
PS - Palestinian Territory 7
TH - Thailandia 7
BG - Bulgaria 6
GE - Georgia 6
HN - Honduras 6
PA - Panama 6
ET - Etiopia 5
KW - Kuwait 5
AL - Albania 4
CH - Svizzera 4
HU - Ungheria 4
JM - Giamaica 4
KR - Corea 4
LY - Libia 4
PT - Portogallo 4
SN - Senegal 4
TT - Trinidad e Tobago 4
XK - ???statistics.table.value.countryCode.XK??? 4
EU - Europa 3
GY - Guiana 3
TW - Taiwan 3
AU - Australia 2
BH - Bahrain 2
BW - Botswana 2
CM - Camerun 2
GH - Ghana 2
KG - Kirghizistan 2
ME - Montenegro 2
MN - Mongolia 2
MW - Malawi 2
NG - Nigeria 2
NI - Nicaragua 2
QA - Qatar 2
SR - Suriname 2
TZ - Tanzania 2
Totale 23.679
Salva come PNG Salva come JPEG
Città #
Fairfield 1.825
Ashburn 1.278
Woodbridge 1.179
Singapore 1.051
Hong Kong 875
Chandler 815
Houston 795
Jacksonville 767
Seattle 720
Wilmington 619
San Jose 604
Cambridge 598
Ann Arbor 454
Nyköping 366
Beijing 299
Roxbury 227
Lawrence 225
Nanjing 205
New York 203
Lauterbourg 198
Princeton 142
Abidjan 134
Boardman 133
Des Moines 126
Helsinki 121
Los Angeles 116
São Paulo 106
Dallas 105
Ho Chi Minh City 89
San Diego 77
Santa Clara 77
Bari 74
Munich 73
Council Bluffs 71
Hanoi 70
Shenyang 66
Dong Ket 65
Inglewood 65
Buffalo 52
Brooklyn 50
Nanchang 50
Hebei 49
Jakarta 49
London 48
Dublin 46
Rio de Janeiro 45
Milan 42
Rome 40
Brussels 35
Jiaxing 34
Tianjin 34
Tokyo 28
Chicago 27
The Dalles 27
Baghdad 26
Columbus 26
Johannesburg 26
Paris 25
Curitiba 24
Nuremberg 24
Frankfurt am Main 22
Moscow 22
Tashkent 22
Warsaw 21
Belo Horizonte 20
Mexico City 20
Turku 20
Nairobi 19
Taranto 19
Changsha 18
Mumbai 18
Toronto 18
Brasília 17
Campinas 17
Lahore 17
Orem 17
San Francisco 17
Atlanta 16
Montreal 16
Norwalk 16
Pune 16
Quito 16
Denver 15
Dhaka 15
Falls Church 15
Riyadh 15
Jeddah 14
New Delhi 14
Chennai 13
Guayaquil 13
Kuala Lumpur 13
Medellín 13
Porto Alegre 13
Amman 12
Boston 12
Buenos Aires 12
Caracas 12
Da Nang 12
Guangzhou 12
Stockholm 12
Totale 16.461
Salva come PNG Salva come JPEG
Nome #
Influence of HLA-B18 on liver fibrosis progression in a cohort of HIV/HCV coinfected individuals 372
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 367
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated with Incident and Prevalent Type 2 Diabetes in Persons Living with HIV 224
Access to health services for undocumented immigrants in Apulia. 207
Variability OF HIV-1 V2 env domain for integrin binding: Clinical correlates 197
Cerebrospinal fluid compartmentalization of HIV-1 and correlation with plasma viral load and blood–brain barrier damage 192
HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ? 187
Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART 187
HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen 186
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. 180
Aeromonas sobria sepsis complicated by rhabdomyolysis in an HIV-positive patient: case report and evaluation of traits associated with bacterial virulence 176
An outbreak of HIV-1 BC recombinants in Southern Italy 174
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 174
Potential diagnostic properties of chest ultrasound in thoracic tuberculosis—A systematic review 174
An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia 169
Amoebic hepatic abscesses in an HIV-positive patient 165
Aeromonas sobria sepsis complicated by rhabdomyolysis in an HIV-positive patient: case report and evaluation of traits associated with bacterial virulence 164
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 159
Reduced community viral load does not coincide with a reduction in the rate of new HIV diagnoses and recent infections: data from a region of southern Italy 157
HIV-1 coreceptor tropism: A syllogistic connection with the veterans aging cohort study index and the CD4/CD8 ratio 157
Comment on: Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection 157
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 156
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 156
The elderly and direct antiviral agents: Constraint or challenge? 155
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort. 155
Local epidemics gone viral: Evolution and diffusion of the Italian HIV-1 recombinant form CRF60_BC 155
Chronic Inflammation in a Long-Term Cohort of HIV-Infected Patients According to the Normalization of the CD4:CD8 Ratio 153
Prevalence of urinary schistosomiasis in migrants in Apulia, a region of southern Italy, in the years 2006-2016 153
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 152
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 151
HIV tropism and its relationship with transmitted resistance in naive patients 150
Improved virological outcome in non-B patients: a possible role for baseline coreceptor tropism 149
Prevalence and Clinical Characteristics of Mycobacterial Diseases in the Barletta-Andria-Trani Province, Italy (2005-2013) 149
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 149
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 148
Co-receptor switch during HAART is independent of virological success 146
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 146
Access to Health Services for Undocumented Immigrants in Apulia 144
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference 143
Limiting severe outcomes and impact on intensive care units of moderate-intermediate 2009 pandemic influenza: role of infectious diseases units. 140
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 140
Cryoglobulinemia in subjects with HCV infection alone, HIV infection and HCV/HIV coinfection 139
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies 139
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA <50 cp/mL 139
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 139
Social determinants of therapy failure and multi drug resistance among people with tuberculosis: A review 138
Prevalence of diabetes mellitus in newly diagnosed pulmonary tuberculosis in Beira, Mozambique 138
Liver abscess due to Fusobacterium necrophorum in an immunocompetent patient 137
The at risk child clinic (ARCC): 3 years of health activities in support of the most vulnerable children in Beira, Mozambique 135
A multidrug-resistant (MDR) HIV type 1 infection in a homosexual man and identified source patient 134
Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression 134
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 133
The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy. 132
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 132
CD4 and CD4/CD8 ratio progression in HIV-HCV infected patients after achievement of SVR 131
Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). 131
Are the proposed env mutations actually associated with resistance to maraviroc? 130
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 129
Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders. 128
HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic 127
Infection caused by Sporothrix schenckii: an autochthonous case in Bari, Southern Italy 127
HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples 126
V3 sequences and paired HIV isolates from 52 non-subtype B HIV type 1-infected patients 126
Mutational patterns of paired blood and rectal biopsies in HIV-infected patients on HAART 126
High HIV-1 diversity in immigrants resident in Italy (2008–2017) 126
Neutralizing antibodies to recombinant alpha-interferon and response to therapy in chronic hepatitis C virus infection 124
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 124
Prevalence of HIV-1 integrase mutations related to resistance to dolutegravir in raltegravir naïve and pretreated patients. 124
Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA) 124
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014 124
Focused ultrasound to diagnose HIV-associated tuberculosis (FASH) in the extremely resource-limited setting of South Sudan: a cross-sectional study 123
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 121
The effect of primary drug resistance on CD4 cell decline and the viral load set-point in HIV positive individuals before the start of antiretroviral therapy. 121
Reduced concentrations of HIV-RNA and TNF-alpha coexist in CSF of AIDS patients with progressive multifocal leukoencephalopathy 120
Difficulties in classifying a/g recombinants: methodological problems or genetic variability? 120
Tuberculosis and diabetes: Current state and future perspectives 120
Genotypic analysis of the protease and reverse transcriptase of non-B HIV type 1 clinical isolates from naïve and treated subjects 119
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 119
Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients 119
Predictors of therapy failure in newly diagnosed pulmonary tuberculosis cases in Beira, Mozambique. 118
Association between HIV p24 antigen in cerebrospinal fluid and severe complications in the central nervous system 117
HIV-1 A1 subtype epidemic in Italy originated from Africa and Eastern Europe and shows a high frequency of transmission chains involving intravenous drug users 116
Recurrent neurosurgical site infection by extensively drug-resistant P. aeruginosa treated with cefiderocol: a case report and literature review 115
Drug Resistance Mutations and Newly Recognized Treatment-Related Substitutions in the HIV-1 Protease Gene: Prevalence and Associations With Drug Exposure and Real or Virtual Phenotypic Resistance to Protease Inhibitors in Two Clinical Cohorts of Antiretroviral Experienced Patients 114
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 114
Pathways of care for HIV infected children in Beira, Mozambique: Pre-post intervention study to assess impact of task shifting 114
A rigorous statistical learning method for the estimation and validation of weighted drug susceptibility scores applied to in vivo virological outcome prediction of atazanavir/ritonavir containing HAART 113
Effects of HIV superinfection on HBV replication in a chronic HbsAg carrier with liver disease 112
Analisi della cinetica replicativa in cultura primaria di isolati di HIV-1 da soggetti in vario stadio di malattia 112
Cell cultures from small amounts of heparinized whole blood enhance HIV-1 isolation rate 112
Gp120 substitutions at positions associated with resistance to fostemsavir in treatment-naive HIV-1-positive individuals 112
Response of severe HIV-associated thrombocytopenia to highly active antiretroviral therapy including protease inhibitors 111
Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis 110
Liver abscess due to Fusobacterium necrophorum in an immunocompetent patient. A case report and review of the literature 110
Evolution of HIV-1 transmitted drug resistance in Italy in the 2007–2014 period: A weighted analysis 109
Uncommon testicular localization of Disseminated TB: a case report from Mozambique 109
Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy. 107
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort. 107
Intracellular and cell-free (infectious) HIV-1 in rectal mucosa 107
Association between HLA class II antigens and hepatitis C virus infection 106
Totale 14.338
Salva come PNG Salva come JPEG
Categoria #
all - tutte 99.750
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.750
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021163 0 0 0 0 0 0 0 0 0 0 0 163
2021/20221.405 74 166 16 91 60 115 70 113 95 94 199 312
2022/20232.291 409 178 114 204 286 314 25 245 406 19 46 45
2023/2024833 69 163 45 48 71 212 29 21 21 23 30 101
2024/20253.390 41 64 362 121 72 310 251 286 166 176 486 1.055
2025/20266.564 978 555 528 809 643 354 833 217 692 710 222 23
Totale 24.291